Comparative Pharmacology
Head-to-head clinical analysis: MYCOBUTIN versus RIFABUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCOBUTIN versus RIFABUTIN.
MYCOBUTIN vs RIFABUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA-dependent RNA polymerase in Mycobacterium tuberculosis, blocking RNA synthesis.
Inhibits DNA-dependent RNA polymerase in susceptible bacteria, blocking RNA synthesis.
300 mg orally once daily, or 300 mg twice weekly for MAC prophylaxis in HIV. For TB, 300 mg daily as part of combination therapy.
300 mg orally once daily. For Mycobacterium avium complex (MAC) prophylaxis, 300 mg once daily. For active tuberculosis (in combination therapy), 5 mg/kg (up to 300 mg) orally once daily or 5 times weekly.
None Documented
None Documented
Terminal elimination half-life: 35-40 hours (range 30-50 hours). Clinical context: Allows once-daily dosing; prolonged in hepatic or renal impairment.
Clinical Note
moderateRifabutin + Digoxin
"The metabolism of Digoxin can be increased when combined with Rifabutin."
Clinical Note
moderateRifabutin + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Rifabutin."
Clinical Note
moderateRifabutin + Clobetasol propionate
"The serum concentration of Clobetasol propionate can be decreased when it is combined with Rifabutin."
Clinical Note
moderateRifabutin + Estrone sulfate
45 hours (range 32-67 hours) in adults; terminal elimination half-life decreases to 17 hours after repeated dosing due to autoinduction of metabolism.
Renal (30% as unchanged drug), fecal (50-60% as metabolites and parent compound), biliary (minor).
Renal (53% as unchanged drug and metabolites), fecal (30%), with biliary excretion contributing to enterohepatic recycling.
Category C
Category A/B
Antimycobacterial
Antimycobacterial
"The metabolism of Estrone sulfate can be increased when combined with Rifabutin."